Objective: To determine whether technetium-99m-labeled tropane derivative single-photon emission computed tomography (Tc-TRODAT-1 SPECT) provides results comparable to those of the less widely available, less accessible tool fluorine-18-labeled fluorodopa positron-emission tomography (F-FDOPA PET) in the setting of a movement disorders clinic.
Materials And Methods: In this prospective pilot study, eight subjects with a clinical diagnosis of Parkinson's disease were randomly selected from among patients under treatment at a movement disorders clinic and submitted to Tc-TRODAT-1 SPECT and F-FDOPA PET. The results were read by two experienced observers, and a semiquantitative analysis was performed.
Results: The visual and semiquantitative analyses were concordant for all studies, showing that radiotracer uptake in the contralateral striatum on the most affected side was lower when Tc-TRODAT-1 SPECT was employed. The semiquantitative analysis demonstrated a significant correlation between F-FDOPA PET and Tc-TRODAT-1 SPECT (r = 0.73; < 0.01).
Conclusion: It appears that Tc-TRODAT-1 SPECT is a valid option for the study of dopaminergic function in a clinical setting.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354188 | PMC |
http://dx.doi.org/10.1590/0100-3984.2020.0087 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!